# Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

> **NCT05979415** · PHASE2 · TERMINATED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Apomorphine Cartridge

## Key facts

- **NCT ID:** NCT05979415
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-27
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Administrative decision
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05979415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05979415, "Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05979415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*